Pfizer has stunned the medical world, completing the $43 billion acquisition of Seagen, a small drug company that treats turbo cancers and barely makes $2 billion per year. The acquisition means Pfizer becomes the largest oncology company in the world, capable of treating most turbo cancers caused by mRNA vaccines. However, the nature of the acquisition has left many people scratching their heads. Why would Pfizer, flush with the enormous profits it has reaped through its mRNA vaccine, overpay $43 billion for a small cancer drug company? Pfizer does not need the cash. It will also issue $31 billion in...
